These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 7587254)

  • 1. Effects of malignancy and interleukin-2 infusion on gut macromolecular permeability.
    Ryan CM; Atkins MB; Mier JW; Gelfand JA; Tompkins RG
    Crit Care Med; 1995 Nov; 23(11):1801-6. PubMed ID: 7587254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased gut permeability early after burns correlates with the extent of burn injury.
    Ryan CM; Yarmush ML; Burke JF; Tompkins RG
    Crit Care Med; 1992 Nov; 20(11):1508-12. PubMed ID: 1424691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
    Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
    Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The permeability of the barrier of the gastrointestinal tract for the macromolecules of polyethylene glycol-4000: an assessment of the mechanism and its reproducibility].
    Gmoshinskiĭ IV; Verina TIu; Mazo VK; Morozov IA
    Biull Eksp Biol Med; 1992 Nov; 114(11):532-4. PubMed ID: 1290835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II trial of human recombinant interleukin-2 administered as a 4-day continuous infusion for children with refractory neuroblastoma, non-Hodgkin's lymphoma, sarcoma, renal cell carcinoma, and malignant melanoma. A Childrens Cancer Group study.
    Bauer M; Reaman GH; Hank JA; Cairo MS; Anderson P; Blazar BR; Frierdich S; Sondel PM
    Cancer; 1995 Jun; 75(12):2959-65. PubMed ID: 7773948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole body energy expenditure protein breakdown and polyamine excretion during high dose treatment with interleukin-2 and interferon-alpha.
    Naredi P; Hafström L; Zachrisson H; Rudenstam CM; Lundholm K
    Eur J Surg; 1994 Feb; 160(2):67-75. PubMed ID: 8193211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
    Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
    Lindsey KR; Rosenberg SA; Sherry RM
    J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal haemodynamics, sodium and water reabsorption during continuous intravenous infusion of recombinant interleukin-2.
    Geertsen PF; von der Maase H; Olsen NV; Fogh-Andersen N; Nielsen SL; Leyssac PP
    Clin Sci (Lond); 1998 Jul; 95(1):73-81. PubMed ID: 9662488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma.
    Sznol M; Clark JW; Smith JW; Steis RG; Urba WJ; Rubinstein LV; VanderMolen LA; Janik J; Sharfman WH; Fenton RG
    J Natl Cancer Inst; 1992 Jun; 84(12):929-37. PubMed ID: 1629914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parallel determination of gut permeability in man with M(r) 400, M(r) 1500, M(r) 4000 and M(r) 10,000 polyethylene glycol.
    Parlesak A; Bode JC; Bode C
    Eur J Clin Chem Clin Biochem; 1994 Nov; 32(11):813-20. PubMed ID: 7888476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.
    Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF
    J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
    Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
    J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of escalating doses of interleukin-1 beta in combination with a fixed dose of interleukin-2.
    Triozzi PL; Kim JA; Martin EW; Young DC; Benzies T; Villasmil PM
    J Clin Oncol; 1995 Feb; 13(2):482-9. PubMed ID: 7844609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
    Dillman RO; Wiemann MC; Bury MJ; Church C; DePriest C
    Cancer Biother Radiopharm; 1997 Feb; 12(1):5-11. PubMed ID: 10851441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.
    Pichert G; Jost LM; Fierz W; Stahel RA
    Br J Cancer; 1991 Feb; 63(2):287-92. PubMed ID: 1997108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.
    Kradin RL; Kurnick JT; Lazarus DS; Preffer FI; Dubinett SM; Pinto CE; Gifford J; Davidson E; Grove B; Callahan RJ
    Lancet; 1989 Mar; 1(8638):577-80. PubMed ID: 2564111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gut permeability measured by polyethylene glycol absorption in abnormal gut fermentation as compared with food intolerance.
    Eaton KK; Howard M; Howard JM
    J R Soc Med; 1995 Feb; 88(2):63-6. PubMed ID: 7769595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.